Efficacy and safety of pyrotinib‐containing regimen in the patients with HER2‐positive metastatic breast cancer: A multicenter real‐world study

Abstract Background Pyrotinib, a novel irreversible epidermal growth factor receptor 2 (EGFR)/HER2 dual tyrosine kinase inhibitor, has shown promising antitumor efficacy with tolerable toxicity in HER2‐positive metastatic breast cancer (MBC) in several clinical trials. However, the clinical trials d...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Sha Yin, Yajing Chi, Yangyang Du, Jingfen Wang, Changping Shan, Weiwei Yi, Mao Shang, Xiaochu Man, Qiaorui Tan, Huihui Li
Format:	Article
Language:	English
Published:	Wiley 2023-02-01
Subjects:	efficacy HER2‐positive breast cancer pyrotinib real‐world study safety
Online Access:	https://doi.org/10.1002/cam4.5056